Phenylpiracetam hydrazide

Phenylpiracetam hydrazide, also known as fonturacetam hydrazide,[1] is a racetam that is a derivative of phenylpiracetam in which the amide group is replaced with a hydrazide group. It was first reported by a Russian research group in 1980 as part of a series of chemical compounds investigated as anticonvulsants.[2] In an electroshock test it was found to have an ED50 of 310 mg/kg.[2]

Phenylpiracetam hydrazide
Clinical data
Trade namesPhenylpiracetam hydrazide
Other namesFonturacetam hydrazide
Pregnancy
category
  • Unknown
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • US: Not FDA approved; unscheduled
Identifiers
  • 2-(2-oxo-4-phenylpyrrolidin-1-yl)acetohydrazide
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC12H15N3O2
Molar mass233.271 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • c1ccc(cc1)C2CC(=O)N(C2)CC(=O)NN
  • InChI=1S/C12H15N3O2/c13-14-11(16)8-15-7-10(6-12(15)17)9-4-2-1-3-5-9/h1-5,10H,6-8,13H2,(H,14,16) checkY
  • Key:AXQUMNYYLGUJIZ-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Sale on the internet

All piracetam derivatives are not permitted to be sold as dietary supplements in the United States.[3] However, because they lack scheduling, piracetam derivatives like phenylpiracetam hydrazide are sold over the clear net accompanied by indications stating that the compound is "not for human consumption".[4]

See also

References
  1. "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 63" (PDF). WHO Drug Information. 24 (1): 56. 2010. Archived from the original (PDF) on May 21, 2014. Retrieved 26 November 2015.
  2. Glozman OM, Morozov IS, Zhmurenko LA, Zagorevskii VA (1980). "Synthesis and anticonvulsive activity of 4-phenyl-2-pyrrolidinone-1-acetic acid amides". Khimiko-Farmatsevticheskii Zhurnal (in Russian). 14 (11): 43–48.
  3. Cohen PA, Zakharevich I, Gerona R (March 2020). "Presence of Piracetam in Cognitive Enhancement Dietary Supplements". JAMA Internal Medicine. 180 (3): 458–459. doi:10.1001/jamainternmed.2019.5507. PMC 6902196. PMID 31764936. S2CID 208274670.
  4. Musselman ME, Hampton JP (July 2014). ""Not for human consumption": a review of emerging designer drugs". Pharmacotherapy. 34 (7): 745–757. doi:10.1002/phar.1424. PMID 24710806. S2CID 10279777.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.